托伐普坦是一种口服选择性非肽类精氨酸加压素(AVP)V2受体拮抗剂,具有诱导自由水的排泄而不明显降低血清钠的作用。大量临床试验表明其在心力衰竭临床治疗中的应用具有良好前景。本综述通过查阅相关文献,从生理学、药动学、临床疗效及安全性方面,系统阐述托伐普坦在心力衰竭患者中的应用及相关进展。 Tolvaptan is an oral, selective non-peptide arginine vasopressin (AVP) V2 receptor antagonist with the ability to induce excretion of free water without significant reduction of serum sodium. A large number of clinical trials show that its clinical application in heart failure has good prospects. This review systematically expounds the application and progress of tolvaptan in patients with heart failure by referring to relevant literature in terms of physiology, pharmacokinetics, clinical efficacy and safety.